The Centers for Medicare & Medicaid Services will increase the number of opportunities to apply for Healthcare Common Procedure Coding System Level II codes from once per year to quarterly for new drugs and semiannually for new medical devices, the agency announced today, adding that details on the updated process will be forthcoming. Addressing the annual meeting of the Medical Device Manufacturers Association, CMS Administrator Seema Verma said, “We expect this will greatly improve the ability of innovators to accelerate through the adoption curve. On a related note, we’ve been hearing concerns that our Medicare contractors are making decisions to automatically non-cover technologies with category III [Current Procedural Terminology] codes, which are used for emerging technologies … Just this week, we posted answers to commonly asked questions about the LCD process, which explain that contractors are not authorized to make coverage determinations to automatically non-cover any item or service, and must instead follow the new LCD process for each and every local coverage decision they make.”

Related News Articles

Headline
The Food and Drug Administration today released final guidance for transitioning medical device enforcement policies and emergency use authorizations…
Headline
The Food and Drug Administration Friday released a discussion paper on 3D printing of medical devices at the point of care to facilitate input from…
Headline
The Food and Drug Administration Friday cleared for marketing in the U.S. the first fully disposable duodenoscope. The EXALT Model D Single-Use Duodenoscope is…
Headline
The Food and Drug Administration today alerted the public to growing concern about the potential for medical device shortages as facilities that sterilize…
Headline
The Food and Drug Administration last week updated 2017 draft guidance to clarify the categories of clinical and decision support software subject to FDA…
Headline
The Food and Drug Administration today proposed reclassifying surgical staplers for internal use as moderate-risk rather than low-risk medical devices. The…